Education Blog for Healthcare Professionals

Low Molecular Weight Heparins – Osteoporosis?

Occasionally, a patient is treated with long-term low molecular weight heparin (LMWH) (enoxaparin = Lovenox®; Dalteparin = Fragmin®; Tinzaparin = Innohep®) . LMWH may be given because the patient (a) tolerated warfarin poorly (widely fluctuating INRs; significant side-effects, such as marked hair loss or fatigue), (b) had a recurrent thrombotic event which occured with a therapeutic INR, or (c) is pregnant and needs an anticoaglant because of an increased risk for thrombosis. The main side-effect of long-term LMWH is, of course, bleeding.

Whether LMWH cause osteoporosis  is not known, as it has not been appropriately studied. A recent detailed review of the literature concluded that (a) based on the evidence of reported cases and studies there may be a small impact of LMWH on osteoporosis, (b) no large studies have been done to investigate the effect of prolonged LMWH on bone density, (c) large well-designed clinical trials are needed to determine whether LMWH contributes to osteoporosis, and (d) it is impossible to say whether calcium supplementation is beneficial or not in patients treated long-term with LMWH.

My personal approach

In the absence of clinical trial data guiding health care professionals and giving advice to the patient on long-term LMWH, I (a) recommend a once yearly bone density study (DEXA scan), and (b) encourage intake of daily calcium supplementation. No data whatsoever are available on long-term use of fondaparinux (Arixtra®) and osteoporosis. As with LMWH, I recommend a yearly bone density study and calcium supplementation.


Lefkou E et al. Low-molecular weight heparin-induced osteoporosis and osteoporotic fractures: A myth of an existing entity? Lupus 2010;19:3-12.

For patients: The same blog entry, written for patients, is available here.

Disclosure:  I do not have a financial conflict of interest with the content of this post.

Last updated: June 22nd, 2011

Tags: , , , , , , ,

This entry was posted by Clot Connect on at and is filed under Anticoagulants, LMWH, Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.